http://rdf.ncbi.nlm.nih.gov/pubchem/patent/AR-108241-A1
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_451abc949209969590a7e50342cff439 |
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-011 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-38 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1664 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-017 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K38-018 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-42 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-34 |
| filingDate | 2017-04-27-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_abd8258c6432c444f8841316faa6608b http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9eb5c033098835dcb86313c178dc21be |
| publicationDate | 2018-08-01-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | AR-108241-A1 |
| titleOfInvention | EXCIPIENT PROTEIN BASED FOR ACTIVE PHARMACEUTICAL INGREDIENTS |
| abstract | A pharmaceutical formulation comprising a protein-based excipient in combination with an active pharmaceutical ingredient (IFA) wherein said formulation is substantially amorphous and both form a substantially homogeneous mixture; and also with a method to produce said pharmaceutical formulation; and with said pharmaceutical formulation for use as a medicine. Claim 4: The formulation according to any of the preceding claims 1 to 3, characterized in that the protein-based excipient is substantially undenatured, preferably completely undenatured; and / or retains at least part of its biological activity, preferably substantially retains its biological activity; more preferably it almost completely retains its biological activity, more preferably it completely retains its biological activity. Claim 6: The formulation according to any of the preceding claims 1 to 5, characterized in that at least one protein of the protein composition or a hydrolyzate thereof is selected from soy protein, pea protein, blood proteins, immunoglobulins, milk proteins, gelatin, keratin, corn, wheat, hemp, rye, oats, peanuts, barley, casein, albumin, whey protein (lactoalbumin), Hydrolyzed Whey Protein Isolate (HWPI), hydrolyzed collagen, plasma proteins, serum albumin, bovine serum albumin (BSA), human serum albumin (HSA), egg albumin, fish albumin, elastin, collagen, recombinant proteins, artificial proteins, recombinant versions of naturally occurring binding scaffolds, artificial binding scaffolds, and / or a combination thereof; preferably HSA, BSA, gelatin and / or a combination thereof. Claim 10: The formulation according to any of the preceding claims 1 to 9, characterized in that the IFA is selected from the following list: Flubendazole, Carbamazepine, Griseofulvin, Phenytoin, Nifedipine, Verapamil, Azithromycin, Nitrofurantoin, iopanoic acid, ltraconazole, lbuprofen , lndomethacin, Glibenclamide, Bicalutamide, Ezetimibe, Aceclofenac, Ketoconazole, Oxfendazole, Ritonavir, Fenofibrate, Cinnarizine, Darunavir, Diazepam, Testosterone undecanoate, or Naproxen. Claim 17: A method for producing a pharmaceutical formulation characterized in that it comprises: a protein-based excipient that is obtained from a protein composition or a hydrolyzate thereof comprising proteins - as a monomer - at least 10 amino acids in length; and an active pharmaceutical ingredient (IFA); characterized in that said protein-based excipient and said IFA are both substantially amorphous and form a substantially homogeneous mixture; wherein said method comprises at least the steps of: (a) dissolving said IFA using a solvent to obtain a solution; and, (b) drying the solution of step (a) to obtain a powder that is substantially amorphous. Claim 43: A use of a protein composition or a hydrolyzate thereof comprising proteins - as a monomer - of at least 10 amino acids in length characterized in that it is as a protein-based excipient in a formulation according to any one of claims 1 to 17. |
| priorityDate | 2016-04-29-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 100.